Collaboration, open communication, and whole-person care1-3
Talking with patients and exploring how they live with hypertrophic cardiomyopathy (HCM) can help give a fuller picture to guide patient-centered care3
Algenis,
Diagnosed with HCM in 2022
Actual consented patient.
American Heart Association/American College of Cardiology (AHA/ACC)/Multisociety 2024 Guidelines strongly recommend shared decision-making between people with HCM and their care team to provide the best clinical care1*
Collaboration and open communication between a person with HCM and clinician can aid in the development of a care plan that fits the patient’s1,4:
- Lifestyle
- Activity level
- Goals
Patient-reported outcome (PRO) tools can enable insights on quality of life and functional status from the patient’s point of view and can enhance HCM care5,6
Some PRO tools that can be used in HCM include6-8:
- KCCQ (Kansas City Cardiomyopathy Questionnaire)
- SAQ-7 (Seattle Angina Questionnaire 7-level)
- EQ-5D (EuroQoL 5-dimension)
HCM is a debilitating and life-changing condition5,9
Inability to participate in normal activities, whether work or social, can have an impact on a person’s identity.10
People with HCM may also carry the burden of knowing that genetic testing may impact their family, employment, insurance, and relationships.10
In interviews, people with HCM revealed the following self-reported disruptions5†:
A multidisciplinary team can help provide whole-person care to people with HCM—the team can include cardiologists, psychologists, nurses, social workers, dietitians, and other specialties to help address both their physical and psychological needs.1,11
By embracing the whole person throughout their journey, Cytokinetics is committed to helping improve the lives of those with HCM.
Allison,
Diagnosed with HCM in 2020
Actual consented patient.
Next: Learn about the diagnostic challenges of HCM
Clinical decisions remain with the healthcare provider.
*Multisociety includes American Medical Society for Sports Medicine, Heart Rhythm Society, Pediatric and Congenital Electrophysiology Society, and Society for Cardiological Magnetic Resonance.1
†Interviews conducted in 2017 and 2018 among 27 people with HCM. These interviews were conducted as part of a conceptual model to better understand the symptoms and impacts of people with HCM. The HCM status of some participants (obstructive vs nonobstructive) was unconfirmed.5
References: 1. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(23):e1239-e1311. doi:10.1161/cir.0000000000001250. Available at: https://www.jacc.org/doi/epdf/10.1016/j.jacc.2024.02.014 2. Fioretti C, Magni E, Barlocco F, et al. Doctor-patient care relationship in genetic cardiomyopathies: an exploratory study on clinical consultations. PLoS One. 2020;15(8):e0236814. doi:10.1371/journal.pone.0236814 3. Zytnick D, Heard D, Ahmad F, Cresci S, Owens AT, Shay CM. Exploring experiences of hypertrophic cardiomyopathy diagnosis, treatment, and impacts on quality of life among middle-aged and older adults: an interview study. Heart Lung. 2021;50(6):788-793. doi:10.1016/j.hrtlng.2021.06.004 4. Martinez MW. Hypertrophic cardiomyopathy and exercise: mutually exclusive or beneficial? Clin Sports Med. 2022;41(3):473-484. doi:10.1016/j.csm.2022.02.011 5. Zaiser E, Sehnert AJ, Duenas A, Saberi S, Brookes E, Reaney M. Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life. J Patient Rep Outcomes. 2020;4(1):102. doi:10.1186/s41687-020-00269-8 6. Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76(20):2379-2390. doi:10.1016/j.jacc.2020.09.542 7. Coats CJ, Maron MS, Abraham TP, et al. Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design. JACC Heart Fail. 2024;12(1):199-215. doi:10.1016/j.jchf.2023.10.004 8. Ho CY, Olivotto I, Jacoby D, et al. Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy. Circ Heart Fail. 2020;13(6):e006853. doi:10.1161/CIRCHEARTFAILURE.120.006853 9. Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379(7):655-668. doi:10.1056/NEJMra1710575 10. Subasic K. Living with hypertrophic cardiomyopathy. J Nurs Scholarsh. 2013;45(4):371-379. doi:10.1111/jnu.12040 11. Rashid S, Gulfam A, Noor TA, et al. Anxiety and depression in heart failure: an updated review. Curr Probl Cardiol. 2023;48(11):1-22. doi:10.1016/j.cpcardiol.2023.101987